Skip to Main Content

Paper Details

Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Am J Hematol
17
2022
AML, Decitabine, Down syndrome, FLAG, G-CSF, R/R AML, childhood leukemia and lymphoma, cytarabine, decitabine, fludarabine, gene, hematopoietic stem cell, leukemogenesis, patients, relapsed/refractory pediatric acute myeloid leukemia, vorinostat
Author NameAffiliation
Van HuynhChildren's Hospital of Orange County
Patrick BrownJohns Hopkins University
Patrick BrownJohns Hopkins University
Bill H ChangOregon Health and Science University
Rajen ModyUniversity of Michigan Medical School ann arbor
David S ZieglerKids Cancer Centre, Sydney Children's Hospital
David S ZieglerUniversity of New South Wales
Alan S WayneCancer and Blood Disease Institute, Children's Hospital Los Angeles
Alan S WayneUSC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Alan S WayneCancer and Blood Disease Institute, Children's Hospital Los Angeles
Alan S WayneUSC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
  • 1 - 11

Datasets